B6.Cg-Ifngr1^tm1Agt Ifnar1^tm1.2Ees/J

Stock number: 029098
Product name: Ifngr1 Ifnar1 double knockout
Research areas: Cancer Research, Cell Biology Research, Immunology, Inflammation and Autoimmunity Research, Research Tools, Virology Research

Description

These C57BL/6J-congenic Ifngr1 Ifnar1 double mutant animals harbor knockout alleles of the receptors for interferon-γ and interferon-α/β. When homozygous for each allele, the double knockout mice exhibit a reduced immune response and increased susceptibility to infectious agents. These mice may be useful in studying antiviral immune responses, as well as interferon stimulation. Mouse mutants involving these genes have been used in studies of Zika virus pathogenesis.

Detailed description

These C57BL/6J-congenic Ifngr1 Ifnar1 double mutant animals harbor null alleles of the receptors for interferon-γ and interferon-α/β. The phenotype of each individual mutation is described below. When homozygous for each null allele, the Ifngr1 Ifnar1 double knockout mice (Ifngr1 Ifnar1 dKO) may have even greater susceptibility to certain infections/agents. These mice may be useful in studying antiviral immune responses, as well as interferon stimulation. Mouse mutants involving these genes have been used in studies of Zika virus pathogenesis.

Ifngr1 encodes the ligand-binding chain (alpha) of the heterodimeric IFN-γ receptor (found on macrophages). Ifnar1 encodes the type-I interferon-α/β receptor (type-I IFN receptor). Binding of their ligands (type-II IFN and type-I IFN, respectively) activates JAK-STAT signaling pathways critical for regulating growth, survival, differentiation, pathogen resistance and antiviral immune responses.

The Ifngr1 null allele (Stock No. 003288), often referred to as 'G129' when maintained on a 129 genetic background, encodes a non-functional protein lacking the cytoplasmic domain needed for signaling. Mice singly homozygous for this null allele (Ifngr1^-/-) have normal T cell responses but are defective in natural resistance, evidenced by an increased susceptibility to infection by Listeria monocytogenes and vaccinia virus. Homozygotes are viable and fertile with the immune deficiencies described above.

The Ifnar1 null allele (from Stock No. 028288) has exon 3 deleted; resulting in a non-functional protein (the exon 2-4 splice variant and frameshift leads to translation of 11 arbitrary (missense) amino acids within the N-terminal extracellular domain followed by a stop codon). Mice singly homozygous for this null allele (Ifnar1^-/-) lack type-I IFN receptor function; leading to reduced immune response and increased susceptibility to viral infection. For example, in response to Pneumocystis lung infection, Ifnar1^-/- animals develop a transient bone marrow crisis largely due to loss of neutrophils. Homozygous null mice are viable and fertile, with the immune deficiencies described above. Heterozygous mice are viable and fertile with no reported abnormalities.

Similar to other immunodeficient strains, maintaining Ifnar1^-/- mice in high health status (specific pathogen-free) vivaria promotes overall colony health. If homozygous null animals are maintained in low health barrier rooms, the use of medicated water (e.g., sulfatrim/trimethoprim-sulfa or enrofloxacin/Baytril) is suggested to increase overall colony health.

 

Development

The C57BL/6J-congenic Ifngr1 Ifnar1 double mutant animals were created in 2016 by breeding mice harboring the Ifngr1 null allele (Stock No. 003288) with mice harboring the Ifnar1 null allele (Stock No. 028288). Each null allele is described below.

The Ifngr1 null targeted mutation (Ifngr1^tm1Agt; often called 'G129' when on a 129 genetic background) was designed by Dr. Michel Aguet (University of Zurich). This has a neomycin cassette inserted into exon V (encoding an extracellular membrane-proximal portion of the receptor) of the interferon-γ receptor 1 locus (Ifngr1) on chromosome 10. C57BL/6J-congenic (N10) mice harboring the Ifngr1 null allele (Stock No. 003288) were used for creating the Ifngr1 Ifnar1 double mutant animals.

The Ifnar1 null allele (Ifnar1^tm1.2Ees) was designed by Dr. Edward E. Schmidt (Montana State University) to have a deletion of exon 3 of the type-I interferon-α/β receptor locus (Ifnar1) on chromosome 16. C57BL/6J-congenic (N5) mice harboring the Ifngar1 null allele (Stock No. 028288) were used for creating the Ifngr1 Ifnar1 double mutant animals.

Allele

Symbol: Ifngr1^tm1Agt
Name: targeted mutation 1, Michel Aguet
MGI accession ID: MGI:1857286
Generation method: Targeted
Attributes: Null/Knockout
Synonyms: G129; IFn type II receptor; IFN-gamma R-; IFN-gamma R⁰; IFN-gammaR-; IFNgammaR KO; IFN-gammaR KO; IFN-gamma-R KO; IFN-gammaR^-; IFN-gammaR⁰; IFN-gammaR1^-; IFN-gammaRalpha^_; Ifngr-; IFNgR KO; Ifngr1^-
Marker symbol: Ifngr1
Marker name: interferon gamma receptor 1
Marker synonyms: CD119; Ifgr; IFN-gamma R; IFN-gammaR; Ifngr; IMD27A; IMD27B; Nktar
Chromosome: 10
Strain of origin: 129S7/SvEvBrd-Hprt1⁺
Molecular note: Insertion of a neomycin cassette into exon V, which encodes an extracellular membrane-proximal portion of the receptor.

Allele

Symbol: Ifnar1^tm1.2Ees
Name: targeted mutation 1.2, Edward E Schmidt
MGI accession ID: MGI:5692167
Generation method: Targeted
Attributes: Null/Knockout
Marker symbol: Ifnar1
Marker name: interferon (alpha and beta) receptor 1
Marker synonyms: AVP; Ifar; IFN-alpha/betaR; IFN-alpha-REC; IFNAR; IFNBR; IFRC; IMD106
Chromosome: 16
Strain of origin: (C57BL/6 x 129S6/SvEvTac)F1
Molecular note: The targeting vector was designed to insert a self-excising FRT-Prm1pFlppol2Neo-FRT cassette and loxP site in intron 2, and a second loxP site in intron 3 of the gene. Facilitated self-excision of the cassette in the male germline and resulted in offspring with one FRT site and loxP site upstream of exon 3, and a second loxP site downstream of exon 3. Cre-mediated recombination removed the floxed neo cassette and exon 3. The resulting non-functional protein contains an exon 2-4 splice variant and frameshift leading to translation of 11 arbitrary (missense) amino acids within the N-terminal extracellular domain followed by a stop codon.